漳州片仔癀药业股份有限公司关于控股股东首次增持公司股份计划的公告

Group 1: Shareholding Increase Plan - The controlling shareholder, Jiujiang Group, holds 307,522,643 shares, accounting for 50.97% of the total share capital of the company [2] - Jiujiang Group plans to increase its shareholding from February 1, 2026, to July 31, 2026, with a total investment of no less than RMB 300 million and no more than RMB 500 million [2] - The increase will be executed through the Shanghai Stock Exchange trading system without a set price range, depending on stock price fluctuations and market trends [2][3] Group 2: Clinical Trial Announcement - The company has completed the enrollment of the first subject in the Phase I clinical trial of PZH2113 capsules, which is expected to have no significant impact on the company's financial status and operating performance for the year [10] - PZH2113 capsules are a Class 1 innovative drug with independent intellectual property rights, targeting relapsed/refractory non-Hodgkin lymphoma [10][12] - The global market for diffuse large B-cell lymphoma is projected to exceed USD 20 billion by 2030, indicating a significant unmet clinical need [12]